새로 진단된 MGMT 비메틸화 교모세포종에 대한 일반적인 치료(테모졸로마이드 및 방사선 요법)와 비교한 면역 요법 약물 Ipilimumab 및 Nivolumab 플러스 방사선 요법의 사용 테스트
새로 진단된 MGMT(종양 O-6-메틸구아닌 DNA 메틸트랜스퍼라제) 비메틸화 교모세포종 환자에서 Ipilimumab 및 Nivolumab 대 Temozolomide의 무작위 II/III상 공개 라벨 연구
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
PRIMARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs progression-free survival (PFS) versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. (Phase II) II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs overall survival (OS) versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation. (Phase III)
SECONDARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs PFS versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation for the phase III part of the study.
II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly increases the 2-year OS rate versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation.
III. To evaluate the safety of adding ipilimumab and nivolumab to radiotherapy via comparative frequency between arms of specific adverse events of interest and frequency summaries for all adverse event types.
IV. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on patient reported outcomes (PROs), as measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) in patients with newly diagnosed GBM without MGMT promoter methylation.
V. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on selected Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in patients with newly diagnosed GBM without MGMT promoter methylation.
VI. To evaluate the impact of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on neurocognitive function (NCF) in patients with newly diagnosed GBM without MGMT promoter methylation.
EXPLORATORY OBJECTIVES:
I. To explore biomarkers in pre-treatment archival tumor tissue that may predict efficacy of ipilimumab and nivolumab as measured by OS, PFS, and 2-year OS rate, such as but not limited to:
Ia. PDL1 expression; Ib. Mutational burden. II. To explore (in the two treatment separately) whether the MGMT protein expression correlates with clinical outcomes including OS, PFS, and 2-year OS rate.
III. To evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide orally (PO) daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain magnetic resonance imaging (MRI) throughout the trial.
ARM 2: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab intravenously (IV) over 90 minutes once every 4 weeks (Q4W) for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial.
After completion of study treatment, patients are followed up every 3 months for year 1, then every 4 months for year 2, and then every 6 months thereafter.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
- 3단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Anaheim, California, 미국, 92806
- Kaiser Permanente-Anaheim
-
Auburn, California, 미국, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, 미국, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Concord, California, 미국, 94520
- John Muir Medical Center-Concord
-
La Jolla, California, 미국, 92093
- UC San Diego Moores Cancer Center
-
Loma Linda, California, 미국, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, 미국, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, 미국, 90048
- Cedars Sinai Medical Center
-
Ontario, California, 미국, 91761
- Kaiser Permanente-Ontario
-
Orange, California, 미국, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Roseville, California, 미국, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, 미국, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, 미국, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, 미국, 95817
- University of California Davis Comprehensive Cancer Center
-
Torrance, California, 미국, 90509
- Torrance Memorial Medical Center
-
Torrance, California, 미국, 90505
- Torrance Memorial Physician Network - Cancer Care
-
Walnut Creek, California, 미국, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Colorado Springs, Colorado, 미국, 80907
- Penrose-Saint Francis Healthcare
-
Denver, Colorado, 미국, 80210
- AdventHealth Porter
-
Littleton, Colorado, 미국, 80122
- AdventHealth Littleton
-
Parker, Colorado, 미국, 80138
- AdventHealth Parker
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06102
- Hartford Hospital
-
New Britain, Connecticut, 미국, 06050
- The Hospital of Central Connecticut
-
-
Delaware
-
Lewes, Delaware, 미국, 19958
- Beebe Medical Center
-
Millville, Delaware, 미국, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, 미국, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, 미국, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, 미국, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, 미국, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, 미국, 19971
- Beebe Health Campus
-
-
Florida
-
Jacksonville, Florida, 미국, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, 미국, 32803
- AdventHealth Orlando
-
-
Georgia
-
Augusta, Georgia, 미국, 30912
- Augusta University Medical Center
-
Savannah, Georgia, 미국, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, 미국, 31404
- Memorial Health University Medical Center
-
Thomasville, Georgia, 미국, 31792
- Lewis Hall Singletary Oncology Center
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, 미국, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, 미국, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, 미국, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, 미국, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, 미국, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, 미국, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, 미국, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, 미국, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, 미국, 96813
- Island Urology
-
Kailua, Hawaii, 미국, 96734
- Castle Medical Center
-
Lihue, Hawaii, 미국, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, 미국, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, 미국, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, 미국, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, 미국, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Boise, Idaho, 미국, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, 미국, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, 미국, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, 미국, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, 미국, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, 미국, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, 미국, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, 미국, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, 미국, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, 미국, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, 미국, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, 미국, 60611
- Northwestern University
-
Chicago, Illinois, 미국, 60612
- University of Illinois
-
Danville, Illinois, 미국, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, 미국, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, 미국, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, 미국, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, 미국, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, 미국, 62401
- Carle Physician Group-Effingham
-
Elmhurst, Illinois, 미국, 60126
- Elmhurst Memorial Hospital
-
Eureka, Illinois, 미국, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, 미국, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, 미국, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, 미국, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, 미국, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, 미국, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, 미국, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, 미국, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, 미국, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, 미국, 61938
- Carle Physician Group-Mattoon/Charleston
-
Naperville, Illinois, 미국, 60540
- Edward Hospital/Cancer Center
-
O'Fallon, Illinois, 미국, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, 미국, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, 미국, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, 미국, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, 미국, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, 미국, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, 미국, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, 미국, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, 미국, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, 미국, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, 미국, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, 미국, 62702
- Springfield Clinic
-
Springfield, Illinois, 미국, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, 미국, 61801
- Carle Cancer Center
-
Urbana, Illinois, 미국, 61801
- The Carle Foundation Hospital
-
Warrenville, Illinois, 미국, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington, Illinois, 미국, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, 미국, 46202
- IU Health Methodist Hospital
-
-
Iowa
-
Ames, Iowa, 미국, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, 미국, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, 미국, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, 미국, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, 미국, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, 미국, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, 미국, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, 미국, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, 미국, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, 미국, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, 미국, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, 미국, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, 미국, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, 미국, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70112
- Tulane University School of Medicine
-
New Orleans, Louisiana, 미국, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, 미국, 04401
- Eastern Maine Medical Center
-
Bath, Maine, 미국, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Belfast, Maine, 미국, 04915
- MaineHealth Waldo Hospital
-
Brewer, Maine, 미국, 04412
- Lafayette Family Cancer Center-EMMC
-
Portland, Maine, 미국, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, 미국, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, 미국, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, 미국, 04074
- Maine Medical Partners Neurology
-
Scarborough, Maine, 미국, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, 미국, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bel Air, Maryland, 미국, 21014
- UM Upper Chesapeake Medical Center
-
Columbia, Maryland, 미국, 21044
- Central Maryland Radiation Oncology in Howard County
-
Glen Burnie, Maryland, 미국, 21061
- UM Baltimore Washington Medical Center/Tate Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, 미국, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, 미국, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, 미국, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, 미국, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, 미국, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, 미국, 48118
- Chelsea Hospital
-
Dearborn, Michigan, 미국, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, 미국, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, 미국, 48503
- Hurley Medical Center
-
Flint, Michigan, 미국, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, 미국, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, 미국, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, 미국, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, 미국, 49048
- Beacon Kalamazoo
-
Livonia, Michigan, 미국, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, 미국, 48341
- Michigan Healthcare Professionals Pontiac
-
Royal Oak, Michigan, 미국, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, 미국, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, 미국, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, 미국, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, 미국, 48085
- Corewell Health Beaumont Troy Hospital
-
Warren, Michigan, 미국, 48093
- Henry Ford Health Warren Hospital
-
West Branch, Michigan, 미국, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, 미국, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, 미국, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, 미국, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, 미국, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, 미국, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, 미국, 55433
- Mercy Hospital
-
Edina, Minnesota, 미국, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, 미국, 55432
- Unity Hospital
-
Maple Grove, Minnesota, 미국, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, 미국, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, 미국, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, 미국, 55454
- Health Partners Inc
-
Saint Louis Park, Minnesota, 미국, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, 미국, 55101
- Regions Hospital
-
Saint Paul, Minnesota, 미국, 55102
- United Hospital
-
Stillwater, Minnesota, 미국, 55082
- Lakeview Hospital
-
-
Mississippi
-
Jackson, Mississippi, 미국, 39216
- University of Mississippi Medical Center
-
Southhaven, Mississippi, 미국, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Cape Girardeau, Missouri, 미국, 63703
- Saint Francis Medical Center
-
-
Montana
-
Billings, Montana, 미국, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, 미국, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, 미국, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, 미국, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, 미국, 59901
- Logan Health Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, 미국, 68123
- Nebraska Medicine-Bellevue
-
Lincoln, Nebraska, 미국, 68516
- Cancer Partners of Nebraska
-
Omaha, Nebraska, 미국, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, 미국, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, 미국, 68118
- Nebraska Medicine-Village Pointe
-
-
New Hampshire
-
Lebanon, New Hampshire, 미국, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- Hackensack University Medical Center
-
Livingston, New Jersey, 미국, 07039
- Saint Barnabas Medical Center
-
Morristown, New Jersey, 미국, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, 미국, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, 미국, 08903
- Rutgers Cancer Institute of New Jersey
-
Pennington, New Jersey, 미국, 08534
- Capital Health Medical Center-Hopewell
-
Summit, New Jersey, 미국, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, 미국, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, 미국, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, 미국, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, 미국, 14642
- University of Rochester
-
Syracuse, New York, 미국, 13210
- State University of New York Upstate Medical University
-
West Islip, New York, 미국, 11795
- Good Samaritan University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, 미국, 28210
- Atrium Health Pineville/LCI-Pineville
-
Concord, North Carolina, 미국, 28025
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Bismarck, North Dakota, 미국, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, 미국, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, 미국, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, 미국, 44304
- Summa Health System - Akron Campus
-
Cleveland, Ohio, 미국, 44106
- Case Western Reserve University
-
Cleveland, Ohio, 미국, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, 미국, 43214
- Riverside Methodist Hospital
-
Dublin, Ohio, 미국, 43016
- Dublin Methodist Hospital
-
-
Oklahoma
-
Lawton, Oklahoma, 미국, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, 미국, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, 미국, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, 미국, 97015
- Providence Cancer Institute Clackamas Clinic
-
Gresham, Oregon, 미국, 97030
- Legacy Mount Hood Medical Center
-
Newberg, Oregon, 미국, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, 미국, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, 미국, 97213
- Providence Portland Medical Center
-
Portland, Oregon, 미국, 97225
- Providence Saint Vincent Medical Center
-
Portland, Oregon, 미국, 97227
- Kaiser Permanente Northwest
-
Tualatin, Oregon, 미국, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, 미국, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Broomall, Pennsylvania, 미국, 19008
- Crozer-Keystone Regional Cancer Center at Broomall
-
Chadds Ford, Pennsylvania, 미국, 19317
- Christiana Care Health System-Concord Health Center
-
Lancaster, Pennsylvania, 미국, 17601
- Lancaster General Ann B Barshinger Cancer Institute
-
Lancaster, Pennsylvania, 미국, 17602
- Lancaster General Hospital
-
Monroeville, Pennsylvania, 미국, 15146
- Forbes Hospital
-
Philadelphia, Pennsylvania, 미국, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, 미국, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, 미국, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
Pittsburgh, Pennsylvania, 미국, 15232
- UPMC-Shadyside Hospital
-
West Reading, Pennsylvania, 미국, 19611
- Reading Hospital
-
Wexford, Pennsylvania, 미국, 15090
- Wexford Health and Wellness Pavilion
-
-
South Carolina
-
Rock Hill, South Carolina, 미국, 29730
- Rock Hill Radiation Therapy Center
-
-
South Dakota
-
Pierre, South Dakota, 미국, 57501
- Avera Cancer Institute at Pierre
-
Sioux Falls, South Dakota, 미국, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, 미국, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, 미국, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Collierville, Tennessee, 미국, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, 미국, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Houston, Texas, 미국, 77030
- Memorial Hermann Texas Medical Center
-
San Antonio, Texas, 미국, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
American Fork, Utah, 미국, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, 미국, 84720
- Sandra L Maxwell Cancer Center
-
Logan, Utah, 미국, 84321
- Logan Regional Hospital
-
Murray, Utah, 미국, 84107
- Intermountain Medical Center
-
Ogden, Utah, 미국, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, 미국, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, 미국, 84065
- Riverton Hospital
-
Salt Lake City, Utah, 미국, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, 미국, 84143
- LDS Hospital
-
St. George, Utah, 미국, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Berlin Corners, Vermont, 미국, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, 미국, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, 미국, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- Inova Schar Cancer Institute
-
Richmond, Virginia, 미국, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, 미국, 23970
- VCU Community Memorial Health Center
-
-
Washington
-
Seattle, Washington, 미국, 98101
- Virginia Mason Medical Center
-
Vancouver, Washington, 미국, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, 미국, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
-
West Virginia
-
Wheeling, West Virginia, 미국, 26003
- Wheeling Hospital/Schiffler Cancer Center
-
-
Wisconsin
-
Burlington, Wisconsin, 미국, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Germantown, Wisconsin, 미국, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, 미국, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, 미국, 54311
- Aurora BayCare Medical Center
-
Johnson Creek, Wisconsin, 미국, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
Kenosha, Wisconsin, 미국, 53142
- Aurora Cancer Care-Kenosha South
-
Madison, Wisconsin, 미국, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, 미국, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, 미국, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, 미국, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, 미국, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, 미국, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, 미국, 54017
- Cancer Center of Western Wisconsin
-
Oshkosh, Wisconsin, 미국, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, 미국, 53406
- Aurora Cancer Care-Racine
-
Sheboygan, Wisconsin, 미국, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, 미국, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, 미국, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wauwatosa, Wisconsin, 미국, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, 미국, 53227
- Aurora West Allis Medical Center
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
PRIOR TO STEP 1 REGISTRATION:
-
No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other testing are ineligible and should not be registered)
-
Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin & eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status. Note that tissue for central pathology review and central MGMT assessment must be received by the New York University (NYU) Center for Biospecimen Research and Development (CBRD) on or before postoperative calendar day 23. If tissue cannot be received by postoperative calendar day 23, then patients may NOT enroll on this trial as central pathology review will not be complete in time for the patient to start treatment no later than 6 weeks following surgery. Results of central pathology review and central MGMT analysis will generally be conveyed to NRG Oncology within 10 business days of receipt of tissue. Note: In the event of an additional tumor resection(s), tissue must be received within 23 days of the most recent resection and the latest resection must have been performed within 30 days after the initial resection. Surgical resection (partial or complete) is required; a limited biopsy is not allowed because it will not provide sufficient tissue for MGMT analysis
- Note: The central pathology review and central MGMT results determine eligibility. Therefore, patients may be offered the opportunity to consent REGARDLESS of local pathology and MGMT results, and consent can occur BEFORE local pathology interpretation is finalized and BEFORE local MGMT testing is conducted
-
Contrast-enhanced brain MRI within 3 days after surgery
- MRI with Axial T2 weighted FLAIR {preferred} or T2 turbo spin echo (TSE)/fast spin echo (FSE) and 3-dimensional (3D) contrast-enhanced T1 sequences are required
- 3D pre contrast-enhanced T1 sequences are strongly suggested
-
Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception hormonal or barrier method of birth control; or abstinence during and after treatment
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
-
PRIOR TO STEP 2 REGISTRATION:
-
Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review
- Note: diagnoses of "Molecular glioblastoma" per the Consortium to Inform Molecular and Practical Approaches to Central Nervous System (CNS) Tumor Taxonomy (c-IMPACT-NOW) criteria or "CNS grade 4" per the World Health Organization (WHO) 2021 criteria are NOT relevant
-
MGMT promoter without methylation confirmed by central pathology review. Note: Patients with tissue that is insufficient or inadequate for analysis, fails MGMT testing, or has indeterminate or methylated MGMT promoter are excluded.
- Note: central pathology review and central MGMT results determine eligibility; local pathology or MGMT results cannot be used for eligibility/randomization
- Note: patients with methylated MGMT may be considered for enrollment on NRG-BN011
-
IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e IDH wildtype). (If a mutation is identified then the patient will be ineligible and must be registered as ineligible at step 2.)
- Note: this test is not being performed in real time as part of central review and will not be provided to sites from a centrally performed test
-
History/physical examination within 28 days prior to step 2 registration
-
Karnofsky Performance Status (KPS) >= 70 within 28 days prior to step 2 registration
-
Neurologic function assessment within 28 days prior to step 2 registration
-
Age >= 18 years
-
Hemoglobin >= 10 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) (within 7 days prior to step 2 registration)
-
Leukocytes >= 2,000/mm^3 (within 7 days prior to step 2 registration)
-
Absolute neutrophil count >= 1,500/mm^3 (within 7 days prior to step 2 registration)
-
Platelets >= 100,000/mm^3 (within 7 days prior to step 2 registration)
-
Total bilirubin =< 1.5 x institutional/lab upper limit of normal (ULN) (within 7 days prior to step 2 registration)
-
Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (within 7 days prior to step 2 registration)
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
For women of childbearing potential (WOCBP), negative serum or urine pregnancy test within 7 days prior to step 2 registration. Note that it may need to be repeated if not also within 3 days prior to treatment start
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes
Exclusion Criteria:
-
Prior therapy for tumor except for resection. For example, prior chemotherapy, immunotherapy, or targeted therapy for GBM or lower grade glioma is disallowed (including but not limited to temozolomide, lomustine, bevacizumab, any viral therapy, ipilimumab or other CTLA-4 antibody, PD-1 antibody, CD-137 agonist, CD40 antibody, PDL-1 or 2 antibody, vaccine therapy, polio or similar viral injection as treatment for the tumor, and/or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) as is prior Laser interstitial thermal therapy (LITT), Gliadel wafer, radiotherapy, radiosurgery, gamma knife, cyber knife, vaccine or other immunotherapy, brachytherapy, or convection enhanced delivery;
- Note that 5-aminolevulinic acid (ALA)-mediated fluorescent guided resection (FGR) photodynamic therapy (PDT) or fluorescein administered prior to/during surgery to aid resection is not exclusionary and is not considered a chemotherapy or intracerebral agent
-
Current or planned treatment with any other investigational agents for the study cancer
-
Definitive clinical or radiologic evidence of metastatic disease outside the brain
-
Prior invasive malignancy (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years
-
Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields
-
Pregnancy and nursing females due to the potential teratogenic effects and potential risk for adverse events in nursing infants
-
History of severe hypersensitivity reaction to any monoclonal antibody
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or temozolomide
-
On any dose of any systemically administered (oral, rectal, intravenous) corticosteroid within 3 days prior to step 2 registration. Inhaled, topical, and ocular corticosteroids are allowed without limitation but must be recorded. Note that treatment with systemically administered corticosteroid after initiating study treatment is allowed as needed
-
Patients with known immune impairment who may be unable to respond to anti-CTLA 4 antibody
-
History of interstitial lung disease including but not limited to sarcoidosis or pneumonitis
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, defined as New York Heart Association functional classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, are excluded, as are patients on active immunosuppressive therapy. These include but are not limited to: patients with a history of immune-related neurologic disease, CNS or motor neuropathy, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as autoimmune vasculitis [e.g., Wegener's Granulomatosis]), systemic lupus erythematosus (SLE), connective tissue diseases (e.g., systemic progressive sclerosis), scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome, Hashimoto's thyroiditis, autoimmune hepatitis are excluded because of the risk of recurrence or exacerbation of disease
-
Exceptions: patients with a history of the following conditions are not excluded, unless receiving active immunosuppressive therapy:
-
Vitiligo
-
Type I diabetes
-
Rheumatoid arthritis and other arthropathies
-
Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA)
- Anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
-
-
Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation are also excluded
-
Current or planned therapy with warfarin
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Arm I (radiation therapy, temozolomide)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide PO daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
다른 이름들:
Ancillary studies Given PO
다른 이름들:
Undergo radiation therapy
다른 이름들:
Undergo contrast-enhanced brain MRI
다른 이름들:
Wear Optune device
다른 이름들:
|
|
실험적: Arm II (radiation therapy, ipilimumab, nivolumab)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab IV over 90 minutes Q4W for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
다른 이름들:
Given IV
다른 이름들:
Ancillary studies Given IV
다른 이름들:
Undergo radiation therapy
다른 이름들:
Undergo contrast-enhanced brain MRI
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free Survival (PFS) (Phase II)
기간: From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
|
Overall Survival (OS) (Phase III)
기간: From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PFS for the Entire Cohort (Phase II/III)
기간: From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Overall Survival at 2 Years
기간: From randomization to two years
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Two-year survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to two years
|
|
Number of Participants by Highest Grade Adverse Event Reported
기간: From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Change in MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) Symptom Severity at Six Months (Patient Reported Outcomes)
기간: Baseline and six months
|
The MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Symptom Severity subscale is a patient-reported outcome measure that assesses the severity of symptoms experienced by patients with brain tumors over the previous 24 hours. Possible subscale scores range from 0 to 10, with higher scores indicating a worse outcome. The change score was calculated as the 6-month value minus the baseline value. A negative change reflects improvement at 6 months and a positive change reflects decline at 6 months. |
Baseline and six months
|
|
Time to Neurocognitive Failure
기간: From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
Neurocognitive failure is defined as the first instance of neurocognitive decline in any of six assessments, as determined by the reliable change index: Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test (TMT) part A, TMT part B, and Controlled Oral Word Association (COWA). Failure time is defined as time from randomization to failure, disease progression or death (competing events), or last follow-up (censored). Neurocognitive failure rates and median failure times are estimated using the cumulative incidence method. Participants with no baseline or no follow-up neurocognitive function data were censored at day 1. |
From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
|
Number of Participants With Most Severe Response for Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 6 Months
기간: Six months
|
Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). The last response of each of the lists is the most severe response. |
Six months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
OS(연구가 2상에서 중단되는 경우)
기간: 연구 2단계가 끝나면
|
연구 2단계가 끝나면
|
|
|
Tumor Biomarker Analyses
기간: Up to 4 years
|
Will assess PD-L1 expression and mutational burden expression specifically. |
Up to 4 years
|
|
MGMT Protein Expression
기간: Up to 4 years
|
Will assess the prognostic value of MGMT protein expression (in terms of predicting clinical outcomes such as PFS, OS, and 2-year OS rate) in the two treatment arms, separately. In addition, will evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms. Correlation methods and survival modeling will be used to address these questions. |
Up to 4 years
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Andrew B Lassman, NRG Oncology
간행물 및 유용한 링크
일반 간행물
- Woroniecka K, Fecci PE. Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. Neuro Oncol. 2020 Sep 29;22(9):1233-1234. doi: 10.1093/neuonc/noaa170. No abstract available.
- Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Sep 20;43(27):3032-3040. doi: 10.1200/JCO-25-00618. Epub 2025 Aug 8.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 신생물
- 조직학적 유형에 따른 신생물
- 신생물, 선상 및 상피
- 신경교종
- 신생물, 신경상피
- 신경외배엽 종양
- 신생물, 생식 세포 및 배아
- 신생물, 신경 조직
- 교육종
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 조사 기술
- 치료학
- Azoles
- 약리학 적 행동
- 화학 작용 및 용도
- 생물학적 요인
- 물리적 현상
- 다 카르 바진
- 트리아 젠
- 이미 다졸
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 화학 물질의 특수 용도
- 화학 기술, 분석
- 스펙트럼 분석
- 수용체, 세포 표면
- 막 단백질
- 항원
- 항원, 표면
- 바이오 마커
- 화학 물질의 진단 사용
- 수용체, 면역 학적
- 항원, 분화, T- 림프구
- 항원, 분화
- 면역 체크 포인트 단백질
- 값 감금 및 억제 T- 세포 수용체
- 테모졸로마이드
- 니볼루맙
- 이필리무맙
- 방사선 요법
- 방사
- 자기 공명 분광법
- 대비 미디어
- CTLA-4 항원
기타 연구 ID 번호
기타 연구 ID 번호
- NCI-2020-03404
- U10CA180868 (미국 NIH 보조금/계약)
- NCI-2020-03404 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- NRG-BN007 (기타 식별자: CTEP)
- NRG-BN007 (기타 식별자: NRG Oncology)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .